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Abstract
Background: In a previous paper, we had assumed that the risk of screen-detected breast cancer mostly reflects
inherent risk, and the risk of whether a breast cancer is interval versus screen-detected mostly reflects risk of masking.
We found that inherent risk was predicted by body mass index (BMI) and dense area (DA) or percent dense area (PDA),
but not by non-dense area (NDA). Masking, however, was best predicted by PDA but not BMI. In this study, we aimed
to investigate if these associations vary by tumor characteristics and mode of detection.
Methods: We conducted a case-control study nested within the Melbourne Collaborative Cohort Study of 244 screen-
detected cases matched to 700 controls and 148 interval cases matched to 446 controls. DA, NDA and PDA were
measured using the Cumulus software. Tumor characteristics included size, grade, lymph node involvement, and
ER, PR, and HER2 status. Conditional and unconditional logistic regression were applied as appropriate to estimate the
Odds per Adjusted Standard Deviation (OPERA) adjusted for age and BMI, allowing the association with BMI to be a
function of age at diagnosis.
Results: For screen-detected cancer, both DA and PDA were associated to an increased risk of tumors of large
size (OPERA ~ 1.6) and positive lymph node involvement (OPERA ~ 1.8); no association was observed for BMI and NDA.
For risk of interval versus screen-detected breast cancer, the association with risk for any of the three mammographic
measures did not vary by tumor characteristics; an association was observed for BMI for positive lymph nodes
(OPERA ~ 0.6). No associations were observed for tumor grade and ER, PR and HER2 status of tumor.
Conclusions: Both DA and PDA were predictors of inherent risk of larger breast tumors and positive nodal status,
whereas for each of the three mammographic density measures the association with risk of masking did not vary
by tumor characteristics. This might raise the hypothesis that the risk of breast tumours with poorer prognosis,
such as larger and node positive tumours, is intrinsically associated with increased mammographic density and
not through delay of diagnosis due to masking.
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Background
Mammographic density (MD) is a risk factor for breast
cancer [1–5] and is also known to play a role in the
masking of the tumor [1, 2, 5]. What is unclear is
whether the influences of MD on inherent risk and
masking vary by tumor characteristics. Knowledge on
this might aid to understand the aetiology of breast can-
cer. Specifically, understanding if the dense tissues of the
breast give rise to breast tumors of a specific kind might
aid in understanding the biological mechanisms involved
in the development of breast tumors. Understanding if
masking varies by tumor characteristics might highlight
the difference in the biology of the various tumors.
In a previous paper [6], we postulated that the risk of
screen-detected breast cancer is mostly influenced by in-
herent risk, while risk of interval breast cancer is due to
a combination of inherent risk and risk of masking.
Therefore, given a woman participating in a screening
program is diagnosed with breast cancer, the factors as-
sociated to the likelihood of having a screen-detected
versus an interval cancer will mostly be those that influ-
ence risk of masking. We reported in the paper that in-
herent risk was predicted by body mass index (BMI) and
dense area (DA) or percent dense area (PDA), but not
by non-dense area (NDA), whereas masking was best
predicted by PDA but not BMI [6].
Very few studies have analysed the association be-
tween MD and risk of breast cancer by tumor character-
istics, separately for each detection mode [7–10]. Of
these one study did not adjust for BMI [9], the rest did
not allow for the association between BMI and risk to
vary by age [7, 8, 10] and none of them had investigated
the concurrent associations of dense area (DA), percent
dense area (PDA) and non-dense area (NDA).
For screen-detected cancer, studies have observed that
higher density was associated with increased risk of lar-
ger tumors [7, 10] and nodal involvement [7] after
adjusting for BMI. Results for interval cancer are more
varied. One study observed a negative association be-
tween density and histologic grade, differentiation and
mitotic index after adjusting for BMI but there was no
statistically significant difference in the risk estimates be-
tween screen-detected and interval cases [10]. This
might not be surprising as 66% of the interval cases were
true interval cases thus, the risk of interval cancer would
most likely reflect inherent risk similar to risk of screen-
detected cancer as postulated in our paper. Another
study had combined interval cases with clinically de-
tected cases (i.e. women with breast symptoms referred
to for mammography) and reported density to be po-
sitively associated for oestrogen (ER)- and triple-negative
tumors [8] and larger tumors [7] after adjusting for BMI.
Here we have used the same case-control study nested
within the Melbourne Collaborative Cohort Study (MCCS)
analysed before [6], to investigate if the association be-
tween DA, PDA and NDA and inherent risk of breast can-
cer, and the risk of masking vary by tumor characteristics,
specifically size, grade, lymph node involvement, and ER,
progesterone (PR), and human epidermal growth factor re-
ceptor 2 (HER2) status.
Methods
The MCCS is a prospective cohort study, which started
recruiting participants from the Melbourne metropolitan
area between 1990 and 1994. At study entry there were
41,514 participants (including 24,469 women) aged be-
tween 27 and 76 years. A nested case-control study was
designed based on the subset of MCCS women who had
been identified to have attended BreastScreen Victoria, a
population-based screening program, through a record
linkage conducted in 2009 (20,444 women). Cases were
women who subsequently had a first diagnosis of inva-
sive adenocarcinoma of the breast (International Classifi-
cation of Diseases for Oncology codes C50.0–C50.9).
Four controls were matched to each case by year of
birth, year of entry into the MCCS and country of origin.
The mammogram with craniocaudal view and closest to
study entry was chosen for measurement. Screen-
detected cases were identified at BreastScreen Victoria.
Cases diagnosed within 2 years of a negative screen at
BreastScreen Victoria were defined as interval cases.
There were 244 screen-detected cases matched to 700
controls and 148 interval cases matched to 446 controls.
Further details about the nested case-control study have
been published elsewhere [6, 11, 12].
Tumor characteristics
The Victorian Cancer Registry (VCR) reviewed the path-
ology reports and classified the cancers according to
tumor size, tumor grade, lymph node involvement, and
ER, PR, and HER2 status. The original diagnostic tumor
slides were retrieved for 85% of the cases from pathology
laboratories and reviewed by a single pathologist (C.
McLean) who assessed ER, PR, and HER2 status using
immunohistochemistry techniques [13]. ER and PR tu-
mors were categorized as positive if ≥ 1% of the nuclei
were stained and/or the intensity of staining was weak,
moderate, or strong and negative otherwise; HER2 tu-
mors were categorized as positive if > 10% of the nuclei
were stained and the intensity of staining was weak,
moderate, or strong and negative otherwise. The agree-
ments between the ER, PR, and HER2 status assessed by
immunohistochemistry and the records held by the VCR
were 91%, 70%, and 72%, respectively (for ER, κ = 0.56,
P < 0.0001; for PR, κ = 0.30, P < 0.0001; for HER2, κ =
0.32, P < 0.0001). Given the good agreement between the
ER, PR, and HER2 data, when archival tumor tissue was
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not available, ER, PR, and HER2 status was assigned ac-
cording to the histopathology reports held at the VCR.
Statistical analyses
Associations between the mammographic measures and
risk were estimated in terms of odds per adjusted stand-
ard deviation (OPERA) according to models with differ-
ent combinations of the variables, DA, PDA, NDA and
BMI, as mentioned in our previous publication [6]. Fur-
ther details about OPERA have been published else-
where [14–16].
Firstly, by applying the Box-Cox method for trans-
forming variables to the mammographic measures of the
control group, DA, PDA and NDA were transformed to
(DA0.2–1)/0.2, (PDA0.2–1)/0.2 and (NDA0.5–1)/0.5, re-
spectively. Linear regression was applied on each trans-
formed mammographic measure, adjusting for age at
mammogram, BMI (standardized according to the con-
trols) and all the matching variables, and the residuals
were standardized to have zero mean and unit variance.
Conditional logistic regression of case-control status was
then applied separately for screen-detected and interval
cancers and for each tumour characteristic. The type-
specific OPERA estimates were obtained by fitting an
interaction term between the standardised residuals and
a set-specific variable equal to the tumour type of the
matching case. Heterogeneity by tumor characteristics
was assessed using likelihood ratio test. Age at mammo-
gram was fitted as a potential confounder.
For the models that included BMI measured at the
MCCS study entry, we fitted an interaction between
BMI (standardized based on the controls) and reference
age (age at diagnosis for the case and for her matched
controls) and its significance was assessed using the like-
lihood ratio test. We have reported the risk estimates for
BMI at ages 50 and 70 to show the predicted risks corre-
sponding to the pre- and postmenopausal age groups.
For the analyses of interval versus a screen-detected
breast cancers, unconditional logistic regression was ap-
plied only to cases adjusted for age at mammogram. As-
sociation between BMI and risk of interval versus a
screen-detected breast cancer did not depended on age
at diagnosis.
The Bayesian information criterion (BIC) and the
area under the receiver operating characteristic curve
(AUC) were used to test for relative goodness of fit.
Differences between AUCs were tested using the De
Long’s tests [17].
Sensitivity analyses were conducted in which we further
adjusted for potential confounders: BMI at age 18–
21 years; age at menarche; parity and lactation; meno-
pausal status; HRT use; OC use; alcohol consumption and
energy intake; and the matching variables (country of
birth, year of birth, year of cohort entry and reference age)
using unconditional logistic regression. We further ad-
justed for family history of breast cancer. A sensitivity
analysis was also conducted by excluding cases diag-
nosed within 2 years from the mammogram, and their
matching controls.
A more detailed explanation of the method used to de-
rive OPERA has been given in our previous publication [6].
Statistical analyses were performed using Stata 12.1
(Stata Corporation, College Station, TX). Two-sided P <
0.05 was considered to be nominally statistically
significant.
Results
As shown in Table 1, screen-detected cases were on
average about 2 to 3 years older than interval cases at
diagnosis (65 years vs 62 years, P < 0.001), at study entry
when covariates were measured (56 years vs 54 years, P
= 0.01), and at the mammogram closest to study entry
(59 years vs 57 years, P < 0.01). Interval cases had on
average greater DA and PDA and lesser total breast area
and NDA than screen-detected cases (P < 0.01). There
was no significant difference in BMI and all the other
confounders except for menopausal status and alcohol
consumption between the two types of cases. Within the
screen-detected cases there were a higher percentage of
menopausal women (P = 0.02) and lower percentage of
alcohol consumers (P < 0.01) at cohort entry than the
interval cases.
ER, PR and HER2 status was known for 95%, 94% and
93% of the cases, respectively. Within the cases with
known ER, PR or HER2 status, 282 (76%) were ER+, 183
(50%) were PR+, and 114 (31%) were HER2+. Grade was
known for 94% of the cases, which included 86 (23%)
well differentiated, 156 (42%) moderately differentiated,
and 126 (34%) poorly differentiated tumors. Lymph
node involvement was known for 93% of the cases of
whom 104 (28%) were node positive. Size of the tumor
was known for 97% of the cases for which 101 (26%)
were < 1 cm, 167 (44%) were between 1 to 2 cm and
114 (30%) were ≥ 2 cm.
Interval cases had more tumors with features predict-
ive of poorer prognosis than screen-detected cases; ER-
(30% vs 18%, P < 0.01), PR- (54% vs 43%, P = 0.02),
poorly differentiated tumors (41% vs 27%, P < 0.01), posi-
tive nodal status (44% vs 16%, P < 0.001) and larger
tumor size, ≥ 2 cm (44% vs 20%, P < 0.001).
Table 2 shows that both DA and PDA were positively
associated with risk of larger breast tumors with an in-
crease in risk of about 80% and 110% for tumors of size
2 cm and greater, respectively, per adjusted SD under all
models (all test for heterogeneity by tumour size, p <
0.01); the risk was significant but lower for tumors of
size 1–2 cm and not significant for smaller tumours of
size lesser than 1 cm. DA and PDA also were positively
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Table 1 Characteristics of study participants
Screen-detected cases Controls Interval cases Controls
(N = 244) (N = 700) (N = 148) (N = 446)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age at baseline, years 56 (8) 56 (8) 54 (8) 54 (8)
Age at mammogram, years 59 (7) 59 (7) 57 (7) 57 (7)
Age at diagnosis, years 65 (7) 62 (7)
Time between age at mammogram and reference age, years 6 (3) 6 (3) 5 (3) 5 (4)
Total energy intake, MJ/day 8.4 (2.9) 8.6 (3.5) 8.7 (3.2) 8.7 (3.1)
BMI, kg/m2
All women 27.5 (4.9) 26.7 (4.9) 26.7 (5.3) 26.5 (4.8)
Premenopausal 27.2 (5.7) 26.2 (5.0) 25.9 (4.9) 26.1 (4.6)
Postmenopausal 27.6 (4.6) 27.0 (4.9) 27.2 (5.5) 26.7 (5.0)
BMI at age 18–21 years, kg/m2 21.5 (2.9) 21.5 (2.9) 21.4 (2.5) 21.5 (2.8)
Breast
Total area, cm2 143.7 (60.9) 137.8 (57.6) 125.0 (56.9) 133.4 (60.3)
Non-dense area, cm2 124.2 (62.1) 120.9 (58.8) 96.5 (55.6) 115.3 (60.6)
Dense area, cm2 19.6 (21.7) 16.8 (20.6) 28.5 (24.5) 18.1 (19.4)
Percent mammographic density, % 15.5 (15.7) 14.0 (15.3) 25.2 (17.9) 15.4 (14.7)
Country of birth N (%) N (%) N (%) N (%)
Anglo Saxon/ Other 204 (84) 583 (83) 123 (83) 371 (83)
Italy 25 (10) 74 (11) 13 (9) 40 (9)
Greece 15 (6) 43 (6) 12 (8) 35 (8)
Age at menarche, years
< 12 47 (19) 125 (18) 31 (21) 75 (17)
12 52 (21) 145 (21) 25 (17) 86 (19)
13 55 (23) 169 (24) 36 (24) 111 (25)
14+ 88 (36) 261 (37) 56 (38) 174 (39)
Parity and lactation
Nulliparous 38 (16) 84 (12) 25 (17) 62 (14)
Parous, never lactated 10 (4) 61 (9) 12 (8) 34 (8)
Parous, lactated 190 (78) 542 (77) 108 (73) 343 (77)
Menopausal status
Premenopausal 69 (28) 195 (28) 59 (40) 170 (38)
Postmenopausal 174 (71) 504 (72) 89 (60) 275 (62)
Hormone replacement therapy use
Never 169 (69) 493 (70) 98 (66) 323 (72)
Ever 74 (30) 205 (29) 49 (33) 122 (27)
Oral contraceptive use
Never 93 (38) 283 (40) 58 (39) 157 (35)
Ever 150 (61) 415 (59) 90 (61) 287 (64)
Alcohol consumption
Lifetime abstainers 109 (45) 257 (37) 43 (29) 160 (36)
Ex-drinkers 13 (5) 24 (3) 3 (2) 13 (3)
Low intake, 1–19 g/day 97 (40) 337 (48) 78 (53) 223 (50)
Medium intake, 20–39 g/day 19 (8) 61 (9) 20 (14) 38 (9)
High intake, ≥ 40 g/day 6 (2) 21 (3) 4 (3) 12 (3)
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associated with positive lymph nodes with risk gradients
of about 90% and 110%, respectively, per adjusted SD
under all models; whereas the risk associated to negative
lymph nodes was lower (all test for heterogeneity by
nodal status, p < 0.01). The model including only PDA
gave the best fit when analysing tumor size (BIC = 1110,
AUC = 0.68) and lymph node involvement (BIC = 1041,
AUC = 0.68). BMI and NDA were not associated with
the size of the tumor and nodal involvement under any
model. None of the three mammographic measures and
BMI were associated with the other tumor characteristics.
Similar to risk of breast cancer overall, DA and PDA
were positively associated with risk of screen-detected
breast tumors of large size and positive lymph node in-
volvement (Table 3). But unlike risk of breast cancer
overall, models including either DA or PDA gave the
best fit when analysing tumor size and lymph node in-
volvement. For tumor size, the model including only
PDA had BIC = 647 and the model including only DA
had a BIC = 648 and both the models had a AUC = 0.64.
For nodal status, the model including only PDA had
BIC = 611 and AUC = 0.63 while the model including
only DA had a BIC = 612 and AUC = 0.64. Both MD
measures were associated with similar risk estimates;
about 60% increase in risk of tumors of size 2 cm and
greater and about 80% increase in risk of positive lymph
nodes. When restricted to small tumors (< 2 cm), the
positive association between MD and positive nodal in-
volvement remained (results not shown). BMI and NDA
were not associated with the size of the tumor and nodal
involvement under any model. None of the three mam-
mographic measures and BMI were associated with the
other tumor characteristics for screen-detected cancer.
The association between risk of interval cancer and
DA, NDA and PDA did not vary by any of the tumor
characteristics (Table 4). Higher BMI was associated
with a decreased risk of negative lymph nodes at 50 years
and increased risk of negative lymph nodes at 70 years.
None of the three mammographic measures were as-
sociated with risk of interval versus screen-detected
breast cancer by any of the tumor characteristics
(Table 5). BMI was negatively associated with risk of
Table 1 Characteristics of study participants (Continued)
Screen-detected cases Controls Interval cases Controls
(N = 244) (N = 700) (N = 148) (N = 446)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Family history of breast cancera
No 185 (76) 548 (78) 101 (68) 341 (76)
Yes 38 (16) 77 (11) 30 (20) 43 (10)
ER
Positive 188 (77.0) 94 (63.5)
Negative 45 (18.4) 45 (30.4)
PR
Positive 126 (51.6) 57 (38.5)
Negative 106 (43.4) 80 (54.1)
HER2
Positive 73 (29.9) 41 (27.7)
Negative 153 (62.7) 96 (64.9)
Grade
Well differentiated 62 (25.4) 24 (16.2)
Moderately differentiated 104 (42.6) 52 (35.1)
Poorly differentiated 65 (26.6) 61 (41.2)
Size
< 1 cm 76 (31.1) 25 (16.9)
1–2 cm 116 (47.5) 51 (34.5)
≥ 2 cm 49 (20.1) 65 (43.9)
Nodal Status
Positive 39 (16.0) 65 (43.9)
Negative 190 (77.9) 71 (48.0)
Abbreviations: BMI body mass index, SD standard deviation
aFamily history of breast cancer is defined as having any relative with breast cancer
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interval versus screen-detected cancer for tumors of 1 to
2 cm in size but not after adjusting for the mammo-
graphic measures. BMI was, however, associated with
decreased risk of interval cancer with positive lymph
nodes compared to screen-detected cancer, both signifi-
cantly and marginally significantly after adjusting for the
mammographic measures (all test for heterogeneity by
nodal status, p = 0.02, 0.03 and 0.06).
The findings above were similar when we adjusted for
all the confounders. No substantial differences in esti-
mates were observed from the sensitivity analyses.
Discussion
As assumed in our previous paper [6], that risk of
screen-detected cancers mostly reflects inherent cancer
risk, and the predictors of interval versus screen-
detected disease mostly reflect predictors of masking, we
found that both DA and PDA are positively associated
with inherent risk of larger breast tumors and positive
nodal involvement. Associations between DA, NDA and
PDA, and risk of masking of tumors did not vary by
tumor characteristics. None of the three mammographic
measures were associated with differential nodal involve-
ment for interval versus screen-detected cancer. How-
ever, BMI was associated with a decreased risk of
positive nodal involvement for interval versus screen-
detected cancer.
Our results are similar to those of a large study con-
sisting of six pooled datasets, which also found DA and
PDA to be associated with increased risk of larger tu-
mors, but found only PDA to be positively associated
with positive nodal status [18]. Unlike our study, the
pooled study [18] had also found DA to be positively as-
sociated with ER+ and PR+ tumors, and NDA to be
negatively associated with the size of the tumor and
HER2+. A meta-analysis [19], however, found no differ-
ential association between MD and risk by ER and
HER2 status of tumors. The differences in the results
could be due to the fact that the previous reports did
not allow the relation between relative risk and BMI to
depend on age.
Some studies analysing screen-detected breast cancer
had also found MD to be associated with increased risk
of larger tumors [7, 10] and positive nodal involvement
[7], and none of them allowed the relation between risk
and BMI to depend on age. Only one study, which did
not adjust for BMI, found no association between MD
and size of the tumor or nodal status for screen-detected
breast cancer [9]. We had interpreted risk of screen-
detected breast cancer to be mainly representative of
risk of developing a detectable breast tumor, assuming
that the cases did not have a detectable tumor at prior
mammograms. As mentioned in our previous paper [6],
this assumption could be reasonable based on a review
[20] which found that within interval cases, which con-
sists of true interval cases, false-negative cases (tumor is
not identified at a mammogram due to reader error) and
occult tumors (tumor is not identified at a mammogram
due to high density), there was a lesser percentage of the
latter two cases; false-negative cases (25–40%) and oc-
cult tumors (8–12%). Our findings, therefore, suggest
there is a biological relationship between the amount of
dense tissues in the breast and faster growth rate of the
tumor. When restricted to small tumors (<2 cm), the
positive association between MD and positive nodal in-
volvement remained which could indicate that besides
faster growth rate, there might be another biological
mechanism that is involved between dense tissues and
spreading of the tumor to the lymph nodes. Overall, this
would support the indication that more frequent screen-
ing schedules should be offered to women with greater
age- and BMI-adjusted MD.
We found no association between any of the mammo-
graphic measures and risk of interval breast cancer by
tumor characteristics. Few studies had investigated risk
by tumor characteristics separately for interval cancer.
One study found greater MD to be associated with in-
creased risk of ER+ interval cancer but it had not ad-
justed for BMI [9]. Another study found an inverse
association between MD and grade of tumor for interval
cancers, but it had only allowed the association between
risk and BMI to be a constant. To our knowledge, none
of the studies had reported on the association between
BMI and risk of interval cancer by tumor characteristics
after adjusting for the mammographic measures. How-
ever, our finding of BMI being associated with increased
risk of interval cancer with positive lymph nodes at age
50 is consistent with earlier studies that had analysed
cases overall [21, 22], while another study found no cor-
relation between the number of lymph nodes affected
and BMI [23]. None of these studies had allowed the as-
sociation with BMI to vary by age and the mean age of
their study participants was younger, between 47 to
50 years. As mentioned in our previous study [6], risk of
interval cancer is more likely a combination of risk of
developing the tumor and risk of masking, and also in-
fluenced by the rate of tumor growth. Consequently, the
results for risk of interval cancer are difficult to
interpret.
We found no association between all three mammo-
graphic measures and risk of interval versus screen-
detected cancer by tumor characteristics. A study which
had further categorised interval cancer into true interval,
false negatives, minimal-sign cancers and occult tumors
also found no association between PDA and risk of each
of the interval cancer category mentioned above com-
pared with screen-detected cancer for the tumor pheno-
type, luminal A, luminal B, HER2 and triple-negative
Krishnan et al. BMC Cancer  (2017) 17:859 Page 21 of 23
[24]. Another study, which had stratified by PDA (low
versus high), found that for women with low PDA, inter-
val cancers were more likely to be HER2+ and have posi-
tive nodal involvement compared with screen-detected
cancers [25]. Both the studies, however, did not adjust
for BMI [24, 25]. Our results for BMI, however, needs to
be confirmed by other studies as to our knowledge this
is the first study to investigate the association between
BMI and risk by tumor characteristic and taking into ac-
count the detection mode.
To our knowledge, our study is the first to estimate
the differential risk of developing breast cancer and risk
of masking by tumor characteristics through investigat-
ing the concurrent associations with all three mammo-
graphic measures, DA, NDA and PDA stratified by
detection mode. BMI has been measured at cohort entry
and we had realistically allowed the BMI association to
vary by age since BMI is known to have differential asso-
ciations on breast cancer risk; BMI is negatively associ-
ated with breast cancer risk for premenopausal women
and positively associated with breast cancer risk for post-
menopausal women [26]. A limitation of our study is the
sample size, especially for small subgroups. Our ER, PR
and HER2 status of tumors was measured by only one
pathologist using immunohistochemistry method which
might lead to non-differential misclassification of the
status of the tumors and this most likely will attenuate
the risk estimates towards null. Other limitations have
been mentioned in our previous paper [6].
Conclusions
We found that both DA and PDA predicted inherent
risk of larger breast tumors and positive nodal status.
There was no differential risk of masking by tumor char-
acteristics associated with DA, NDA and PDA. None of
the three mammographic measures were associated with
differential nodal involvement for interval versus screen-
detected cancer. Our finding suggest that the dense tis-
sues of the breast play a role in faster growth rate of the
tumor and in spreading of the tumor to the lymph nodes
that would not be explained by delay of the diagnosis
due to masking.
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